NovAccess Global Inc. XSNX
Set alert
0.00 USD 0.00 0.00%
At close · Nov 2
0.0002 Day range 0.0002
0.0001 52-week range 0.05
- YTD
- 0.00%
- 1 year
- -50.00%
- Open
- 0.0002
- Prev close
- 0.0001
- Mkt cap
- 6.17K
- Vol
- 55.10K
- Avg vol
- 1.18K
- EPS
- -0.06
- P/E
- 0.00
More statistics
- Low
- 0.0002
- High
- 0.0002
- Earnings
- Aug 11, 2023
2Y chart
Signals (40)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Mar 3, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| RSI: Oversold | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
Newest 20 of 40.
Next earnings
Aug 11, 2023
Expected Aug 11, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Jun 1, 2024 | 0.00 | -0.02 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | 0.01 | — | — |
| Feb 9, 2024 | Sep 1, 2023 | 0.00 | -0.08 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
News
- Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)
- NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review
- NovAccess Global Advisory on Annual Meeting of Shareholders
- NovAccess Global Announces New License to Advance its Immunotherapy Platform
- NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
- NovAccess Global Announces $10.7 Million Financing
- NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
- NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
- NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
- NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
Your note
Sign in to keep a note on XSNX — it syncs with the Stock Master app.